Viracta Therapeutics, Inc. (VIRX) Misses Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts VIRX Hot Sheet
Join SI Premium – FREE
Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q4 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31).
For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
- Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
